gMS^®Pro CDMS is a new prognostic test for use with Clinically Isolated Syndrome (CIS) patients who have had their first neurological event. The gMS^®Pro CDMS test will help physicians identify which CIS patients are likely to have a next relapse and convert to Clinically Definite MS (CDMS) within 24 months. Physicians may want to consider treatment for these patients.

The gMS^®Pro CDMS test is a panel of biomarkers. This panel of biomarkers has been studied in multiple patient sample sets. The panel of biomarkers can identify patients that have a greater than 82% probability of suffering from another additional clinical episode within 24 months of the first neurological event. The gMS^®Pro CDMS test is a complementary test to ongoing MRI monitoring of patients and should be used as part of ongoing patient management practice.

The first therapeutic study using the gMS^®Pro CDMS biomarkers is the BEtaferon^® in Newly Emerging multiple sclerosis For Initial Treatment (BENEFIT) study. These markers were validated in this study and Glycominds will continue to study these markers in additional clinical studies with Pharmaceutical companies.

The gMS^®Pro CDMS test will be commercially available in mid 2011.